
With early data from the Oregon Health Authority showing that clients report seeking out psilocybin services in Oregon for a wide range of motivations, one question is how service centers are representing their services to the public.

The Yaden Lab studies psychedelic & other altered states of consciousness. In the Johns Hopkins Center for Psychedelic & Consciousness Research @JHPsychedelics

With early data from the Oregon Health Authority showing that clients report seeking out psilocybin services in Oregon for a wide range of motivations, one question is how service centers are representing their services to the public.

This is an unusual & interesting survey in this space, and I invite you to take it. The idea emerged at a @psychedelethics meeting at Oxford when the group realized we don't have data on what groups in the field think should received more funding/attention. Share your ideas!
🍄 @JHPsychedelics PSYCHEDELIC STAKEHOLDER SURVEY 🔬 There are more promising psychedelic research projects than there is funding. What should take priority? Our new survey is open to anyone with a personal or professional interest in psychedelic science [link below]

Congratulations to former @TheYadenLab postdoc at @JHPsychedelics and now @HopkinsMedicine faculty Dr. Praachi Tiwari on winning this award for her psychedelic research! She is currently setting up a translational psychedelic laboratory at DBB/CPCR here at Hopkins-
Extremely honored to receive this award from @TIFRScience @tifr_alumni. Always grateful for the support of my wonderful colleagues, and so so lucky to have @ViditaVaidya as a mentor!

The first completely on-site preclinical animal study from @JHPsychedelics. An immensely valuable collaboration with Division of Behavioral Biology. So grateful that I got to lead it and work with what can only be called the dream team! Unroll the tweet below for deets 📜
New paper led by @PraachiTiwari, a former postdoc in @TheYadenLab, now faculty at Div of Behavioral Bio & @JHPsychedelics (also w/ @CassieMoorePhD, Brian Jenkins, Elise Weerts, me). We examined how psilocybin affects a broader range of spontaneous behaviors in rats than HTR...

Extremely honored to receive this award from @TIFRScience @tifr_alumni. Always grateful for the support of my wonderful colleagues, and so so lucky to have @ViditaVaidya as a mentor!
Congratulations @PraachiTiwari on the Saraswati Cowsik Award from the TIFR Alumni Association for your paper - super proud :) @TIFRScience @tifr_alumni

There are a number of interesting and increasingly urgent issues in psychedelic law. I spoke to the current state of the scientific evidence at meetings at both Harvard and Yale Law (by way of big face looming on screen for the latter) a couple of weeks ago. More here:
The @SolomonCtrYLS was pleased to host a panel of leading scientific, policy, and legal experts on what psychedelic medicine could mean for the future of mental health treatment. Read the full story here: law.yale.edu/yls-today/news/…

🍄 @JHPsychedelics PSYCHEDELIC STAKEHOLDER SURVEY 🔬 There are more promising psychedelic research projects than there is funding. What should take priority? Our new survey is open to anyone with a personal or professional interest in psychedelic science [link below]

Important work by Dr. @SeanPGoldy et al. to understand the side effects of MDMA doi.org/10.1007/s00213-026-0…
‼️ New paper! MDMA "blue Mondays" & "suicide Tuesdays" are familiar phrases in recreational MDMA culture, describing low points in the days post-use. But do these aftereffects actually exist? Current research shows conflicting results. Thread👇

• Coping strategies: 30% had tried supplements (mostly NAC, acetyl-L-carnitine, magnesium), and interestingly 5% used antidepressants specifically to cope, hinting at preclinical findings on SSRIs mitigating MDMA-induced depletion of serotonin

‼️ New paper! MDMA "blue Mondays" & "suicide Tuesdays" are familiar phrases in recreational MDMA culture, describing low points in the days post-use. But do these aftereffects actually exist? Current research shows conflicting results. Thread👇

🔬 As MDMA-assisted therapy keeps moving toward the clinic, understanding what happens post-treatment matters. So, we (@kelcy_audra, @ExistWell, & @sdpnayak) surveyed 497 US adults with MDMA experience to better understand the phenomenon. Some takeaways:

Open-access link: jmepb.bmj.com/content/2/4/e0…

A growing body of bioethical work has examined ethical issues related to the use of psychedelics in clinical research. With @eddietalksdrugs and @ExistWell, we try to take stock in our state-of-the-field review, published in JME Practical Bioethics.

Had a great time helping represent @TheYadenLab and @JHPsychedelics yesterday at the @FDA's public hearing on psychedelics' therapeutic potential -- big things on the horizon
Representing @TheYadenLab at @JHPsychedelics & @psychedelethics at @FDA. Postdoc Eddie Jacobs @eddietalksdrugs spoke to how the evidence on psychedelic treatments comes from clinical trials, so those safeguards should be used for initial roll-out, to be adjusted based on data…

The first full year of data collected under SB 303 from Oregon's psilocybin services was recently published. With @CaleighPropes & @ExistWell, we examine this data to give a preliminary picture as to how safety and access are being balanced in Oregon’s psilocybin services.

Trial safety data won't transfer cleanly to routine care, and we can't with confidence know which safeguards contribute to it. Record how clinics vary in practice, collect evidence of outcomes, and specify review points and evidential thresholds for loosening safeguards